Is budesonide oral suspension (Eohilia) included in medical insurance reimbursement?

Budesonide oral suspension (Eohilia) is a new topical corticosteroid indicated for the treatment of eosinophilic esophagitis in patients 11 years of age and older. It improves esophageal symptoms through local anti-inflammatory effects, providing safe and effective treatment. However, budesonide oral suspension has not yet been officially launched in China, so it cannot yet be included in the national medical insurance system for reimbursement. For patients who need long-term management of eosinophilic esophagitis, this means that obtaining the drug domestically may require overseas channels or participation in clinical trials. Patients and their families should weigh drug accessibility and economic costs based on doctor's advice.

Medical insurance inclusion involves drug registration, marketing approval and clinical data support. As a topical corticosteroid for oral suspension, budesonide oral suspension has clear efficacy and safety data overseas, but it is still in the introduction stage in the domestic market and needs to complete the drug registration and approval procedures. Once on the market and passed evaluation, the drug is expected to be included in medical insurance, improving patient accessibility, especially for children and adolescent patients who require long-term maintenance treatment, which will significantly reduce the economic burden.

Additionally, while patients and physicians await the official launch of budesonide oral suspension, currently available treatment options for eosinophilic esophagitis may be considered, such as dietary management, other topical or systemic corticosteroids, and allergen-directed interventions. Overseas guidelines emphasize that budesonide oral suspension can significantly reduce systemic side effects due to its local effect. If it is included in medical insurance in the future, its value in clinical practice will be more prominent, especially for patient groups with clear long-term management needs.

Therefore, patients currently using budesonide oral suspension in China need to pay attention to drug import policies, clinical trial information and doctor's advice. At the same time, they must continue to pay attention to the drug's domestic launch and medical insurance inclusion progress, so as to prepare for standardized treatment in the future.

Reference materials:https://www.eohilia.com/